Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors

Next Previous
Trial Profile

A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 26 Nov 2024 According to an Eisbach Bio media release, company announced receipt of a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT), the received grant of US$4.75 million will support the work of Eisbach Bio during the Dose Expansion monotherapy Module 1 of its Phase I/II cancer trial.
  • 16 Sep 2024 According to an Eisbach Bio GmbH media release, this trial is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson), is co-funded with an investment from the Cancer Focus Fund, a unique investment fund established in collaboration with MD Anderson to provide funding and clinical expertise to advance promising cancer therapies.
  • 16 Sep 2024 According to an Eisbach Bio GmbH media release, today announced that first patient has been dosed in Module 1 of this ongoing Phase 1/2 MATCH clinical trial investigating EIS-12656 in solid tumors.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top